Alogliptin
Composition :Ligotin 12.5 Tablet : Each film coated tablet contains Alogliptin 12.5mg (as Alogliptin Benzoate INN).
Ligotin 25 Tablet :Each film coated tablet contains Alogliptin 25mg (as Alogliptin Benzoate INN).
Indications :Alogliptin
is indicated as an adjunct to diet and exercise to improve glycemic control in
adults with type 2 diabetes mellitus.
Dosage and
administration :Individualize the starting dose of
Alogliptin based on the patient's current regimen with or without food. The maximum
recommended dose is 25 mg once daily. No dose adjustment of Alogliptin is
necessary for patients with mild renal impairment (creatinine clearance [CrCI]
>60 mL/min). The dose of Alogliptin is 12.5 mg once daily for patients with
moderate renal impairment (CrCI>30 to <60 mL/min). The dose of Alogliptin
is 6.25 mg once daily for patients with severe renal impairment (CrCI>15 to
<30 mL/min) or with end-stage renal disease (ESRD) (CrCl<15 mL/min or
requiring hemodialysis). Or, as directed by the registered physician.
Use in pregnancy and
lactation :Pregnancy category B . There are no
adequate and well controlled studies in pregnant woman. This tablets should be
used during pregnancy only if clearly needed. Caution should be exercised when
this tablet is administered to a nursing woman.
Storage :Store
below 30° C in a dry place.
Packing :Ligotin 12.5
Tablet : Each box contains 28’s tablets in blister pack.
Ligotin 25 Tablet :Each box contains 30’s tablets in blister pack.
